Chan T Y, Critchley J A
Department of Clinical Pharmacology, Chinese University of Hong Kong.
Drug Saf. 1992 Mar-Apr;7(2):159-61. doi: 10.2165/00002018-199207020-00007.
An elderly patient with congestive heart failure developed serious hyperkalaemia and reversible nonoliguric renal failure during combined therapy with captopril, furosemide (frusemide) and potassium supplements. This case illustrates that such complications can occur late during the course of treatment with angiotensin-converting enzyme (ACE) inhibitors. It is therefore important that both the renal function and plasma potassium are closely monitored in such patients even if these parameters are normal at the beginning of therapy.
一名患有充血性心力衰竭的老年患者在联合使用卡托普利、呋塞米（速尿）和钾补充剂治疗期间出现了严重的高钾血症和可逆性非少尿型肾衰竭。该病例表明，此类并发症可能在血管紧张素转换酶（ACE）抑制剂治疗过程的后期出现。因此，即使这些患者在治疗开始时肾功能和血钾水平正常，密切监测其肾功能和血钾水平也很重要。
